1235005-44-3 Usage
Uses
Used in Pharmaceutical Industry:
N-Fmoc-2,6-difluoro-L-phenylalanine is used as a building block for the synthesis of fluorinated peptides and peptidomimetics for their potential applications in drug discovery and development. The unique chemical and pharmacological properties of these compounds make them valuable in creating new therapeutic agents.
Used in Medicinal Chemistry:
N-Fmoc-2,6-difluoro-L-phenylalanine is used as a key component in the synthesis of novel bioactive compounds, contributing to the advancement of medicinal chemistry by enabling the creation of molecules with specific biological activities.
Used in Chemical Biology:
N-Fmoc-2,6-difluoro-L-phenylalanine is utilized as a molecular probe in chemical biology, aiding researchers in understanding complex biological processes and interactions through the synthesis of tailored fluorinated peptides and peptidomimetics.
Check Digit Verification of cas no
The CAS Registry Mumber 1235005-44-3 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,2,3,5,0,0 and 5 respectively; the second part has 2 digits, 4 and 4 respectively.
Calculate Digit Verification of CAS Registry Number 1235005-44:
(9*1)+(8*2)+(7*3)+(6*5)+(5*0)+(4*0)+(3*5)+(2*4)+(1*4)=103
103 % 10 = 3
So 1235005-44-3 is a valid CAS Registry Number.
1235005-44-3Relevant articles and documents
Kras inhibitory cyclic peptide compound
-
Paragraph 0362; 0617-0618, (2021/06/03)
The following were discovered: a cyclic peptide compound that interacts with Ras; and an unnatural amino acid that is useful in the production of said cyclic peptide compound. The cyclic peptide compound was also discovered to inhibit bonding between Ras and SOS. The following were additionally discovered: a specific unnatural amino acid included in said cyclic peptide compound; and a manufacturing method therefor.
MASP INHIBITORY COMPOUNDS AND USES THEREOF
-
Page/Page column 207, (2020/11/23)
The present invention relates to novel Mannose-binding lectin (MBL)-associated serine protease (MASP) inhibitory compounds, as well as analogues and derivatives thereof, to processes for the preparation thereof, to the use thereof alone or in combinations for treatment and/or prevention of diseases and to the use thereof for production of medicaments for treatment and/or prevention of diseases, especially for treatment and/or prevention of renal and cardiovascular disorders and of ischemia reperfusion injuries.